Evidence map›Paper›PMID 41323119›Full record

ArticleThe Lancet regional health. Western Pacific2025

Risk-stratified classification of pulmonary nodule malignancy via a machine learning model integrating imaging and cell-free DNA: a model development and validation study (DECIPHER-NODL).

Huiting Wang, Hairong Huang, Feng Li, Ying Deng, Changyong Wang, Wei Wei, Song Wang, Dongqin Zhu, Hao Xu, Hua Bao and 18 more

Abstract read
In one paragraph

Article in The Lancet regional health. Western Pacific, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Risk prediction for lung cancer screening: a systematic review and meta-regression.European respiratory review : an official journal of the European Respiratory Society · 2026
    Pooled it
  2. A Noninvasive Circulating Tumor DNA Methylation Classifier to Identify Benign Pulmonary Nodules.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Huiting WangDepartment of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, 510165, China.
Hairong HuangDepartment of Cardiothoracic Surgery, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, 210002, China.
Feng LiDepartment of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, 510165, China.
Ying DengDepartment of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, 510165, China.
Changyong WangDepartment of Cardiothoracic Surgery, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, 210002, China.
Wei WeiDepartments of Esophageal Surgery and Thoracic Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu, China.
Song WangGeneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, 210032, China.
Dongqin ZhuGeneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, 210032, China.
Hao XuGeneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, 210032, China.
Hua BaoGeneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, 210032, China.
Zheng LiDepartment of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, 510165, China.
Wenjun YeDepartment of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, 510165, China.
Yuan ZhangDepartment of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, 510165, China.
Caichen LiDepartment of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, 510165, China.
Bo ChengDepartment of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, 510165, China.
Xiwen LiuDepartment of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, 510165, China.
Liping LiuDepartment of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, 510165, China.
Zheng LiDepartment of Thoracic Surgery and Oncology, Guangzhou National Laboratory, Guangzhou, China.
Jing YangDepartment of Thoracic Surgery and Oncology, Guangzhou National Laboratory, Guangzhou, China.
Wei ChenDepartment of Pulmonology, Taizhou Affiliated Hospital of Nanjing University of Chinese Medicine, Taizhou, 225300, China.
Peng HeGeneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, 210032, China.
Fufeng WangGeneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, 210032, China.
Wen ZhongDepartment of Thoracic Surgery and Oncology, Guangzhou National Laboratory, Guangzhou, China.
Weisheng GuoDepartment of Minimally Invasive Interventional Radiology, The Second Affiliated Hospital, School of Biomedical Engineering Guangzhou Medical University, Guangzhou, China.
Yang ShaoGeneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, 210032, China.
Yi ShenDepartment of Cardiothoracic Surgery, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, 210002, China.
Jianxing HeDepartment of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, 510165, China.
Wenhua LiangDepartment of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, 510165, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Accurate risk stratification of pulmonary nodules is critical for early lung cancer detection. This study aimed to improve malignancy classification and invasiveness prediction using machine learning models integrating low-dose computed tomography (LDCT) radiomics and plasma cell-free DNA (cfDNA) fragmentomics. Methods: This multicenter study enrolled 1356 participants across discovery (n = 1147) and external validation (n = 209) cohorts. A deep learning-based imaging model processed LDCT scans for automated lung nodule detection and malignancy classification. A parallel cfDNA model analyzed four whole-genome fragmentation features: copy number variation, fragment size ratio, fragment-based methylation, and mutation context and signature. The two models were integrated via a stacked ensemble algorithm. An invasion prediction model evaluated tumor aggressiveness. Findings: The integrated imaging-cfDNA model outperformed individual models, with an AUC of 0.950 (95% CI: 0.926-0.975) in the internal test set and 0.966 (95% CI: 0.940-0.991) in the external validation. The combined model's specificity increased to 0.60 (95% CI: 0.49-0.71) while maintaining 95% sensitivity, compared to specificities of 0.50 (95% CI: 0.41-0.59) and 0.33 (95% CI: 0.23-0.44) at equivalent sensitivity levels for the imaging and cfDNA models, respectively. The combined model consistently outperformed the other two models across nodule characteristics, with particular improvement for 10-20 mm and pure solid nodules. The invasion prediction model stratified lung cancers with an AUC of 0.884 (internal) and 0.880 (external). Prediction scores increased stepwise with tumor aggressiveness, from adenocarcinoma in situ to minimally invasive adenocarcinoma, and were highest for invasive adenocarcinoma. Interpretation: This multimodal approach enhances pulmonary nodule risk stratification by integrating radiomic and molecular biomarkers. The model significantly improves diagnostic accuracy, potentially reducing unnecessary procedures while minimizing missed diagnoses, supporting its clinical utility in lung cancer screening. Funding: Noncommunicable Chronic Diseases-National Science and Technology Major Project, National Key Research & Development Programme, China National Science Foundation, the Science and Technology Planning Project of Guangzhou, and Guangzhou National Laboratory.

Indexed as

Cell-free DNALiquid biopsyMachine learningPulmonary noduleRadiomics

Identifiers

PMID41323119
PMCPMC12661453

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.